国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

  .contact us |.about us
News > Lifestyle News ...
Search:
    Advertisement
Cancer vaccine may extend survival
( 2003-08-21 08:51) (China Daily)

The biotechnology company Antigenics Inc said on Monday its experimental cancer vaccine improved survival time in 52 per cent of advanced colon cancer patients who responded to the drug in a small mid-stage clinical trial.

Antigenics, based in New York, said all of the 15 patients who responded immunologically to the vaccine, called Oncophage, were alive two years after treatment, compared with 50 per cent of the 14 patients who did not respond. The disease-free survival rate was 51 per cent for responders and 8 per cent for non-responders.

Typically, patients with advanced colon cancer can expect to live for up to a year, said Garo Armen, chief executive of Antigenics.

"These results are not randomized, but in all the patients who showed an immune response, there has been a trend toward benefit in our clinical trials," he said.

Oncophage is a personalized vaccine derived from an individual patient's tumour. Because the injected drug contains the patient's own genetic codes, it is believed to be more effective in reprogramming the immune system to attack the cancer without side effects.

The vaccine is being studied in a range of cancers, including kidney, pancreatic, skin and gastric cancers.

The first pivotal-stage data on Oncophage is expected later this year, with preliminary results from a Phase 3 kidney cancer trial, Armen said. In that study, patients who have had their cancer surgically removed are either being treated with the vaccine or simply observed, which is the standard of care for patients with that stage of kidney cancer, the CEO explained.

Initial results will be compiled when 80 to 100 of the 600 or so participants have had their cancer return, Armen said. Patients who do relapse are then offered chemotherapy drugs or other toxic therapies.

If the results are promising, Antigenics expects to file for US Food and Drug Administration approval of the vaccine in 2004, he added.

 
Close  
   
  Today's Top News   Top Lifestyle News
   
+Passport application simplified in Beijing
( 2003-08-21)
+Yellow River turns black in first half
( 2003-08-21)
+Land bid plan announced in Shanghai
( 2003-08-21)
+'DIY tourists' swarm to HK, Macao
( 2003-08-21)
+China, WHO join hands in fight against SARS virus
( 2003-08-21)
+Cancer vaccine may extend survival
( 2003-08-21)
+Hope for cancer victims
( 2003-08-21)
+Old band to rock city with new power
( 2003-08-21)
+Tropical storm Vamco reaches east China's Zhejiang Province
( 2003-08-20)
+China's second longest river severely polluted: SEPA
( 2003-08-20)
   
  Go to Another Section  
     
 
 
     
  Article Tools  
     
   
     
   
        .contact us |.about us
  Copyright By chinadaily.com.cn. All rights reserved  






墨玉县|
洛隆县|
蒙阴县|
昔阳县|
加查县|
依安县|
晋州市|
获嘉县|
合作市|
兰西县|
西充县|
沙河市|
南昌市|
会东县|
平遥县|
彭泽县|
田东县|
沙湾县|
濉溪县|
宁南县|
甘德县|
固阳县|
上虞市|
千阳县|
克拉玛依市|
格尔木市|
东乌珠穆沁旗|
武陟县|
天等县|
昌宁县|
民和|
柳江县|
盐津县|
察隅县|
景谷|
门头沟区|
林甸县|
淄博市|
新建县|
漳浦县|
松江区|